Skip to main content

First Tracks Biotherapeutics, Inc Investor Event Transcript, Nov 16, 2026

First Tracks Biotherapeutics, Inc. (TRAX)

First Tracks Bio reported AMB033 produced statistically significant celiac gluten-challenge results across histology and patient-reported symptoms, and committed to late-stage celiac trials in 2027. The healing-cohort readout is expected in the first quarter of 2027. AI summary

Investor Event Transcript 2026-11-16 For: 2026-12-31
Added on November 16, 2026

Conference Transcript - TRAX 2026-11-16

Maureen Godin, Analyst — Jefferies

I'm Maureen Godin. I'm working in the healthcare investment banking team here in London, and it's my pleasure to now introduce Dan Feiga, CEO of First Strikes Biotherapeutics.

Dan Figa, CEO

Well, good afternoon, everyone. Appreciate the Jefferies banking team for the invitation to present here at the conference. These are our forward-looking statements. So First Tracks Bio, we are still technically a young company. We were launched via a spinoff from our predecessor in April of this year. And we are leveraged against a very, I think, accepted platform on potent antibody discovery and early-stage development. What we were able to do with First Tracks six months ago was spin off an ENI with a research organization engine from the prior company, as well as three clinical-stage therapeutics. One is AMB033. We will spend most of this presentation going through this program in detail, the mechanism of action and the development plan. But what I'll start with is we recently announced statistically significant and compelling results, highly compelling results in a celiac trial in a gluten challenge frame. So I'll go through that in detail. But we also have a second trial in celiac ongoing. It's a healing study that we'll read out in the first quarter of next year, as well as a second trial in eosinophilic esophagitis that we'll read out in the third quarter of next year. Our other two programs are Rosnilamab, which is a PD-1 depleter, and AMB-101, which is a BDCA-2 depleter. A couple notes on the BDCA-2. We do have a differentiated profile relative to competitors, namely a large cap with two phase threes reading out in SLE and one in CLE in the beginning of next year. The PD profile is differentiated both on half-life of the antibody as well as the depletion profile targeting the BDCA2 on plasmacytoid dendritic cells. So I'm not going to spend a lot of time on that program in this presentation. We are committing to the presentation of our Phase 1A clinical results next year, and we will announce, following the clinical readouts from the competitor, we will announce our plans forward at that time at some point next year. So now on to AMB033. I think mechanistically, what we are attempting to do here is target and block the CD122 beta subunit, which is presenting in a receptor complex on various immune cells in the setting of disease. So you can see in the picture on the slide on the right. It's a dimeric receptor complex, which we see observed on NK cells, as well as, importantly, CD8 T cells. CD122 also presents in a trimeric receptor complex, which we observe in an activated state on CD4 cells. There are other types of cells that we see in the presence of disease that are relevant for where we are developing the drug. So intraepithelial lymphocytes generally present with a CD8 phenotype in that dimeric receptor. And then ILC2s in the presence of EOE we see in the trimeric receptor. So our program, AMB033, potently blocks the CD122 component of the dimeric or trimeric receptors. What we're doing mechanistically is we're blocking both IL-2 and IL-15 signaling pathways that are important to allow the proliferation and survival of the various... CD4 and CD8 T cells in disease. The other component of this with AMB033 is there are various competitors in a profile. We have a highly potent antagonist being driven by a high affinity. And I'll show you some slides where we think we see differentiation there relative to other folks in the space. So where we are in terms of development path, last year, we finished or initiated and completed a phase 1A trial on Healthy Volunteers. There's about 80 patients that were treated with active drug, both in IV and subcutaneous format. We demonstrated up to a three-week half-life with the subcutaneous administration, full receptor occupancy, and importantly, when you step back from this trial, a safe and tolerable drug overall. We also saw important PD effects in the plasma of the Healthy Volunteers. What we're presenting here on the right-hand side of the page are the impact on both CD8 T cells in the top and NK cells in the bottom. We're showing the CD122 expressing Temra T cells, as well as the CD122 expressing NK cells. We can see with the NK cells, these cells are highly dependent on IL-15 for survival. So I mentioned earlier that we're blocking the signaling of both. For the NK cells, the CD122 representing NK cells, a 98% elimination of these cells from just the initial subcutaneous dosing, so i.e. the lowest dose in the SAD component of the healthy volunteers. You can't do much better than that, and then with the CD8 T cells, a 74% reduction with that initial subcutaneous starting dose. We dosed higher. We did not see any limiting toxicity through the course of the Phase I-A trial. We also performed the MAD components of this. And then lastly, we saw a long-term PD effect. So the NK cells, we had presented publicly. We saw a multi-month, at least three-month reduction of those NK cells before return to baseline off that initial lower subcutaneous starting dose. So before we describe and get into the trial results in celiac disease, a little bit about the mechanism of action of AMB033 as it applies to celiac disease biology. So there's two pathways we like to describe on what's happening in celiac disease. The first is from the initiation of a patient's response to gluten and the downstream byproduct, liodin, that gets picked up by APCs with patients with celiac disease and then presented to CD4 cells that initiate an activation cycle. What's known in this disease is within an hour of C4 activation, i.e. an hour from gluten exposure, you see a rapid uptake of IL-2. That's also associated with a significant increase in inferring gamma. The inferring gamma is one of the initiators of the IL-15 receptor presentation in epithelial cells. So that is the beginning of initiation of then the second. So both of these pathways work together in the context of this disease. What we are doing, as I mentioned earlier with the CD122 antagonists, is we're blocking both IL-15 signaling, which is really important in terms of decreasing the proliferation and the survival of the IELs, which express with the CD8 phenotype, as well as blocking IL-2 signaling, which prevents the initiation or activation of the CD4 cells, which are linked to acute symptoms in this disease. So it's a dual mechanism in terms of blocking the CD122 presentation on the dimeric form and the trimeric form of the various T cells in this disease. So last year, post the phase 1A results, we initiated two different cohorts within celiac disease. A prevention cohort, cohort 1, we're looking at patients on presentation at a VHCD of greater than 2. VHCD is villus height to crypt depth ratio. It's a way to measure the mucosal or the inflammatory injury in the intestine of patients with disease. Greater than 2 is considered moderate or mild disease. For these patients in the first cohort, we gave a baseline subcutaneous dose. At baseline, week day zero, week two, and week four. Then we administered a 14-day gluten challenge of six grams of gluten a day. That's the equivalent of a daily dose of about two to three slices of bread. So we did that continuously for 14 days and did a biopsy at the end of the sixth week. The second cohort in the study is treating the patients who didn't qualify for that gluten challenge. So the patients who enrolled in the second cohort, they had a VHCD initially less than 2.0. We later modified that trial to look at patients less than 2.5 on VHCD. So these are patients with severe or moderate to severe mucosal injury at baseline. Similar to cohort one, we dose patients at week zero, week two, and week four. And however, in this study, we will be looking at the results at week 12 via biopsy. So there's no gluten challenge in this study. We are looking eight weeks from that last dose to see the impact that we've had on drug versus placebo on healing of VHCD as the primary analysis. We have a lot of confidence, based on what I discussed earlier in the Phase 1a results, that we do have a PD effect with a long-term PD effect with a IC90 concentration in tissue based on the tox studies in the Phase 1a through that 12th week. So both these cohorts were initiated at the same time. We read out, and I'll walk through the data from Cohort 1 last month. Cohort 2 has completed enrollment, and we will have those study results in the first quarter of 2027. So here are the baseline characteristics from the cohort one gluten challenge results. I think there's not a lot to see in terms of the differentiation between the number of patients we enrolled, 15 patients in placebo, 17 on drug, so more or less a one-to-one randomization. I think importantly here, and I think consistent with others in the space, we see a baseline VHC that we enrolled in the trial, again, greater than 2.0 in terms of the inclusion criteria. The baseline here is about 2.75 across both arms. So the results. We hit statistical significance on the delta on VHCD. The significance was so far best in disease of 0.49 delta versus placebo. And importantly here, what you can see in the control arm was we saw a decrease of 0.66 on VHCD for the patients who are on placebo. So in only 14 days with 6 grams a day, we saw a very significant deterioration for patients in the control of 0.66. What you could then say was we administered an intense gluten challenge. We know this worked. So beyond just the delta of the drug working relative to the control, it's important to then observe we were preventative of significant deterioration. There's a consensus emerging across KOLs, and there's different answers out there, but general consensus of a minus 0.25 being clinically meaningful. We are lower than that threshold of a decrease of 0.17 on drug, so preventative of damage on drug. You then couple that with one of the important biomarkers. I talked earlier about IELs, intraepithelial lymphocytes, that present themselves and help drive the deterioration of the lining of the gut. We not only showed a statistically significant difference versus the controls, and this is shown on the left. We actually decreased from baseline the number of IELs even in the presence of the gluten challenge. In an intense gluten challenge, it's the first time a company has shown a reduction of IELs in a gluten challenge that was this significant, and that's a pretty radical and important difference. So combined between prevention on VHCD and the IELs, we've shown a robust composite of a histological benefit in this trial. The VCIL is a composite of both. It's a mathematical equation of both the impact on IELs and VHCD. So we hit stats on both the individual components. We hit statistical significance on the combined composite. Then there was the symptomatic impact, and this truly was an upside surprise, and it was to us, even within the company, while the hypothesis was there that by blocking both IL-15 and also IL-2 signaling that we could see a symptom difference, no one has ever seen results like this before presented. So a few things happened. Number one, in the context of that 14-day gluten challenge, the patients on drug saw no increase in symptoms throughout the entire 14 days. Point two, the patients on placebo saw a marked increase immediately on day one that was preserved through the context of that 14-day challenge. Patients didn't drop out, so we really pushed the limits of how much gluten we were giving. Patients didn't drop out, but we did allow concomitant medicines to be used for these patients. The ones on placebo, upon initiation of a symptomatic impact, half of them, approximately half of them, took concomitant medicines. Only one patient self-treated themselves with Tylenol at some point on drug. So... Regardless of the fact that the patients on placebo were taking medicines to manage their symptoms, we saw a statistical difference on day one across the entire CDSD, the select disease symptom diary. This is a validated PRO that we used through the context of the study. Every single day, you're measuring the severity across five different domains, GI symptoms as well as fatigue, from zero being no symptomatic impact to four being severe. On day one, statistical significant difference, that difference was sustained over seven days across the entire CDSD, and over 12 days of the 14-day challenge from moderate to severe. I think it's compounded in the fact that the patients on placebo were taking drugs to manage down symptoms, and we still saw the significance throughout the majority of the trial. This data has not been shown in this significance ever by any other drug. So when you combine the fact that we saw a compelling result in the histology and a compelling result on the PRO, We are excited that it does appear that there's a path forward from the regulatory agencies at this point. We've had interactions, competitors have had interactions, where there is a path forward to show prevention of disease in a registration-enabling trial in the future. So we are going to take the collective information off this data, and we are moving forward to engage in more formal discussions with the data to find what a registration-enabling path moving forward would be, and we have committed publicly that we'll start late-stage trials in 2027. So important to note, and I think it actually really trends well with what we saw on the efficacy side, there is no safety or tolerability challenges with their trial, no patients dropped out, and if anything, what you can see in the context of a gluten challenge here is what you would expect. In fact, on placebo, there's a significant increase in GI symptoms, whereas on the drug, there was not. We saw no SAEs, no severe AEs, and a pretty big difference in moderate AEs given the placebo patients were taking the gluten. Our drug was preventing the symptoms within that chain. So about as good as you can get on the safety and tolerability. So, it's important to note that relative to competing gluten challenges, not all these gluten challenges are the same. We administered six grams a day for 14 days. Other groups are looking at different amounts of gluten over different periods of time. But I think our data does stack up overall, neuroreconics that we hit on, as I mentioned, histology, VHCD, change in IEL density, as well as the symptom benefit. And as we've announced publicly, I think the data stands on its own on a relative basis, but there are nuances in these different trial designs. When you step back from it as a class of CD122 blockers, as well as drugs targeting IL-15s, the class overall is showing a dramatic effect in celiac disease. And I'll talk to the commercial market here for a minute. There is no therapeutic available today to treat patients with celiac disease. Patients with celiac, they are to sustain a gluten-free diet, but regardless of that, are still seeing symptomatic impact and very material impact on inflammatory injury or intestinal injury. One of the interesting proof points is that second cohort that we were enrolling, the healing cohort that reads out in the first quarter, these patients were actually showing up for the trial thinking they were going to be in a gluten challenge. They've been on a gluten-free diet for at least one year. That's an inclusion criteria. They found out via biopsy result that they had severe mucosal injury. So when we think about the context of where this can go commercially, I mentioned earlier across the collective three of us that are targeting the prevention path forward in registration, that's really emerged over the last year, I think, given the quality of the data sets and early engagement with the agency. There is draft guidance that exists to treat patients with celiac disease from four-plus years ago that really discusses healing patients, i.e., something that looks a little bit like our cohort two. So how do you make patients better who have intestinal injury, again, looking at symptomology and histological impact? So there's really two paths forward now, and that's exciting for us in the field. When you look at patients with celiac disease, approximately 2 million. Prevalence-based studies that are linked to biopsy confirmation. A subset of those have been formally diagnosed via biopsy today, but this is a multimillion patient market within the context of the United States alone. We think about 25 to 40%, depending on the study that we looked at, have severe injury. Moving forward, if we could prevent damage as well as clear out inflammation and heal, it really opens up a much larger patient opportunity. The math gets you to well over $20 billion in terms of the treatable population if you really pursue both paths and are successful. A white space market, it's a subset of GIs that treat this in the United States. Preliminary pricing work suggests GI-like biologic pricing, similar to Crohn's and colitis, and multiple paths forward moving from here on out. As I said earlier, second cohort read out in Q1, and we'll have more information in 2027 on the specifics of that registrational path moving forward post-engagement with the agency. We are running an additional trial in EOE. A little bit about the background, the biology of this disease. Quickly, there's one therapeutic that's approved, Dupixin. There's a second, a T-slip that initially we saw data from AstraZeneca about a month ago that was statistically significant on both the histology, i.e. reduction of eosinophils, and on the symptom criteria. It's called the DSQ. So that's really all centered in what we're calling the DUPI-sensitive path. It impacts CD4 cells in ILC2s. That's centered in green. You have some allergen that's activating the CD4 cells. You're seeing, you know, again, a very significant increase in IL-2 and IL-15. As I mentioned earlier, some of the premise of how the CD122 blocker works is winding down. The proliferation and the cytokine secretion of TH2 CD4s, as well as these ILC2 cells. There is a direct link. To CD8 biology and EOE as well. There's a study done by a company called Clipso, which Novartis has acquired. It's the other IL-15 that's in development. In a small number of patients, we showed that by blocking CD8s, you could see what Clipso shows. By blocking IL-15, you're seeing a reduction in CD8s, but also led downstream to reduction of eosinophils. So what's worked in this disease with Dupy and TESI, the T-slip, is targeting the CD4 pathway. There's clinical proof of concept in targeting the CD8 pathway in terms of reduction in eosinophils. That's one of the two co-primer endpoints. As I mentioned earlier, the DSQ is the symptomatic endpoint that we know that is conducive in upstream biology and targeting the inflammation of disease, not necessarily targeting eosinophils directly, but the CD122 antagonist, similar to what's known and what has worked in this disease, We'll be upstream from eosinophil recruitment to clear out inflammation. So that's a bit about the biology within the disease. We have run an animal model, and it's aspergillus-induced eosinophil. We saw a reduction of the eosinophils, both in the esophagus and in the lung. We're the data in the green color on the page on the left-hand side, as well as in the lung ILC2s. There was a measurable amount of ILC2s there as well, and we floored all three cell types of eosinophils. In the two different tissues, you can see the histology in the picture on the right-hand side that's linked to this. I mentioned earlier, you see IL-5 influx that really recruits eosinophils, the eotaxin reduction, so there's a chemokine that's responsible as well for eos recruitment. We're seeing a reduction of those in these animal models too. So the animal model is supportive of the thesis here and how the disease biology works and why we're excited to develop AMB0 through 3 in this disease. So we do have this ongoing trial. It's a 50-patient trial, one-to-one randomization. We are looking at every other week's subcutaneous dosing relative to placebo. At week 12, we will do a scope. We will assess the reduction in eosinophils. We will be measuring the DSQ. It really looks at dysphagia, tightening of the esophagus, the ability to swallow food at that end point. And then we will do a subsequent 12-week off-drug biopsy. We will look at the same endpoints as well and see if there's continued improvement or sustained reduction of eosinophils and on a DSQ at a further time point. So a couple different reads, but the primary analysis and the data that we expect to have in Q3 of next year will be at the week 12 endpoint. This market is driven by the one commercial player today, DePixen. It's estimated that they're selling greater than $3 billion a year in the U.S. alone in EOE. We'll see how the market evolves with. The T-slip that is presumed to be approved in the next year or so, but it is another very large market opportunity. It's still in the market building phase. There's estimated half a million patients or so that would be eligible that are failed to PPI or other earlier forms of treatment prior to receiving something like a dupy. Our TPP is based on a second-line therapy that looks somewhere between TESI and DUPI in terms of the characteristics on both the histology and symptoms. There's clearly upsides from there. We do believe that by targeting both those pathways, you could have better results. But for a second-line market in a very different mechanism of action than these other two drugs, there's another opportunity for patients. As an anecdote, 30-plus percent, closer to 40 percent of patients on DUPI don't see a significant benefit. So last couple of slides quickly. This is a pipeline in a product type of molecule. Across the four players that we've talked about here, including ourselves, we're already in six different diseases. We are committed to a third initiation of disease in vitiligo next year in a Phase II study, as well as a fourth undisclosed indication. So we'll have two additional trials starting up in the first half of next year. We'll be moving forward into later stage trials in celiac disease next year, and we'll have the EOE results in the third quarter of next year, as well as what I mentioned earlier around A&B 101, the BCA2 depleter, that we do believe there's a very good hypothesis of differentiation and path forward. And lastly, we do have ambitions for OSNOMAD to find a way to move the depleter forward there, too. We have approximately $350 million in cash on the balance sheet, and that's about a three-year into the back half of the 2029 runway. So I think I'm timed out here, but if there's any other questions, I'm happy to stay and take them. Thank you for your attention.